Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment.
Angiogenesis
Carbonic anhydrase 2 (CAII)
Lactic acidosis
Tumor endothelial cells
pH regulation
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
17 12 2019
17 12 2019
Historique:
received:
12
09
2019
accepted:
07
11
2019
entrez:
19
12
2019
pubmed:
19
12
2019
medline:
2
10
2020
Statut:
epublish
Résumé
Tumor endothelial cells (TECs) perform tumor angiogenesis, which is essential for tumor growth and metastasis. Tumor cells produce large amounts of lactic acid from glycolysis; however, the mechanism underlying the survival of TECs to enable tumor angiogenesis under high lactic acid conditions in tumors remains poorly understood. The metabolomes of TECs and normal endothelial cells (NECs) were analyzed by capillary electrophoresis time-of-flight mass spectrometry. The expressions of pH regulators in TECs and NECs were determined by quantitative reverse transcription-PCR. Cell proliferation was measured by the MTS assay. Western blotting and ELISA were used to validate monocarboxylate transporter 1 and carbonic anhydrase 2 (CAII) protein expression within the cells, respectively. Human tumor xenograft models were used to access the effect of CA inhibition on tumor angiogenesis. Immunohistochemical staining was used to observe CAII expression, quantify tumor microvasculature, microvessel pericyte coverage, and hypoxia. The present study shows that, unlike NECs, TECs proliferate in lactic acidic. TECs showed an upregulated CAII expression both in vitro and in vivo. CAII knockdown decreased TEC survival under lactic acidosis and nutrient-replete conditions. Vascular endothelial growth factor A and vascular endothelial growth factor receptor signaling induced CAII expression in NECs. CAII inhibition with acetazolamide minimally reduced tumor angiogenesis in vivo. However, matured blood vessel number increased after acetazolamide treatment, similar to bevacizumab treatment. Additionally, acetazolamide-treated mice showed decreased lung metastasis. These findings suggest that due to their effect on blood vessel maturity, pH regulators like CAII are promising targets of antiangiogenic therapy. Video Abstract.
Sections du résumé
BACKGROUND
Tumor endothelial cells (TECs) perform tumor angiogenesis, which is essential for tumor growth and metastasis. Tumor cells produce large amounts of lactic acid from glycolysis; however, the mechanism underlying the survival of TECs to enable tumor angiogenesis under high lactic acid conditions in tumors remains poorly understood.
METHODOLOGY
The metabolomes of TECs and normal endothelial cells (NECs) were analyzed by capillary electrophoresis time-of-flight mass spectrometry. The expressions of pH regulators in TECs and NECs were determined by quantitative reverse transcription-PCR. Cell proliferation was measured by the MTS assay. Western blotting and ELISA were used to validate monocarboxylate transporter 1 and carbonic anhydrase 2 (CAII) protein expression within the cells, respectively. Human tumor xenograft models were used to access the effect of CA inhibition on tumor angiogenesis. Immunohistochemical staining was used to observe CAII expression, quantify tumor microvasculature, microvessel pericyte coverage, and hypoxia.
RESULTS
The present study shows that, unlike NECs, TECs proliferate in lactic acidic. TECs showed an upregulated CAII expression both in vitro and in vivo. CAII knockdown decreased TEC survival under lactic acidosis and nutrient-replete conditions. Vascular endothelial growth factor A and vascular endothelial growth factor receptor signaling induced CAII expression in NECs. CAII inhibition with acetazolamide minimally reduced tumor angiogenesis in vivo. However, matured blood vessel number increased after acetazolamide treatment, similar to bevacizumab treatment. Additionally, acetazolamide-treated mice showed decreased lung metastasis.
CONCLUSION
These findings suggest that due to their effect on blood vessel maturity, pH regulators like CAII are promising targets of antiangiogenic therapy. Video Abstract.
Identifiants
pubmed: 31847904
doi: 10.1186/s12964-019-0478-4
pii: 10.1186/s12964-019-0478-4
pmc: PMC6918655
doi:
Substances chimiques
Carbonic Anhydrase II
EC 4.2.1.-
CA2 protein, human
EC 4.2.1.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
169Références
J Clin Invest. 2013 Sep;123(9):3685-92
pubmed: 23999443
Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
J Neuropathol Exp Neurol. 2006 Jul;65(7):664-74
pubmed: 16825953
J Res Med Sci. 2017 Oct 31;22:117
pubmed: 29184575
IUBMB Life. 2009 Sep;61(9):915-22
pubmed: 19658168
Elife. 2018 May 29;7:
pubmed: 29809145
Cancer Res. 2004 Nov 15;64(22):8249-55
pubmed: 15548691
J Lipid Res. 2018 Feb;59(2):298-311
pubmed: 29208696
J Oncol. 2012;2012:261750
pubmed: 22007214
J Pathol. 2004 Jan;202(1):5-13
pubmed: 14694516
Prostate Cancer Prostatic Dis. 2009;12(1):41-6
pubmed: 18521102
J Biol Chem. 2002 Sep 27;277(39):36085-91
pubmed: 12138085
J Neurosurg. 2009 Sep;111(3):472-7
pubmed: 19216648
Nature. 2014 Sep 25;513(7519):559-63
pubmed: 25043024
Neuro Oncol. 2007 Jul;9(3):308-13
pubmed: 17435181
Am J Respir Cell Mol Biol. 2015 Feb;52(2):183-92
pubmed: 25019941
J Biol Chem. 1995 Dec 29;270(52):31189-95
pubmed: 8537383
Clin Cancer Res. 2005 Nov 15;11(22):8201-7
pubmed: 16299253
J Pathol. 2012 Jun;227(2):189-99
pubmed: 22190257
Oncol Lett. 2016 Mar;11(3):1615-1620
pubmed: 26998052
PLoS One. 2012;7(3):e33418
pubmed: 22428047
Circ Res. 2000 Feb 18;86(3):312-8
pubmed: 10679483
Oncotarget. 2017 Jul 11;8(28):45484-45495
pubmed: 28525375
Oncotarget. 2015 Jun 30;6(18):16198-214
pubmed: 25938544
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
Tumour Biol. 2016 Jul;37(7):9023-35
pubmed: 26762407
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
J Clin Invest. 2008 Dec;118(12):3930-42
pubmed: 19033663
J Biol Chem. 2002 Mar 29;277(13):11368-74
pubmed: 11741977
Dev Biol. 2003 Dec 1;264(1):275-88
pubmed: 14623248
Cancer Lett. 2017 Sep 10;403:339-353
pubmed: 28688971
Cancer Res. 2011 Apr 1;71(7):2550-60
pubmed: 21300765
Br J Cancer. 2013 Oct 15;109(8):2237-47
pubmed: 24045659
Angiogenesis. 1999;3(3):281-8
pubmed: 14517427
Oncotarget. 2016 Dec 27;7(52):86026-86038
pubmed: 27852069
Bioorg Med Chem. 2016 Jul 1;24(13):3043-3051
pubmed: 27234893
Sci Rep. 2016 Jun 13;6:28039
pubmed: 27295191
Am J Pathol. 2012 Mar;180(3):1283-93
pubmed: 22245726
Oncotarget. 2018 Jun 15;9(46):27940-27957
pubmed: 29963253
Mol Med Rep. 2018 Feb;17(2):2937-2944
pubmed: 29257333
Cancer Res. 2009 Jun 1;69(11):4918-25
pubmed: 19458066
Cell Rep. 2015 Mar 3;10(8):1335-48
pubmed: 25732824
Biochem J. 1999 Oct 15;343 Pt 2:281-99
pubmed: 10510291
Front Physiol. 2013 Dec 17;4:370
pubmed: 24381558
Cancer Res. 2006 Nov 15;66(22):10770-7
pubmed: 17108113
Cancer Cell. 2016 Dec 12;30(6):968-985
pubmed: 27866851
Metabolites. 2018 Mar 21;8(2):null
pubmed: 29561812
Am J Pathol. 2012 Mar;180(3):1294-307
pubmed: 22245217
Cancer Sci. 2009 Oct;100(10):1963-70
pubmed: 19650861
Sci Rep. 2014 May 13;4:4927
pubmed: 24820099
Am J Hematol. 2010 Aug;85(8):593-8
pubmed: 20540157
Histochem J. 1995 Dec;27(12):974-82
pubmed: 8789398
Cell Rep. 2018 Dec 11;25(11):3047-3058.e4
pubmed: 30540938